USA flag logo/image

An Official Website of the United States Government

Adjunctive Use of Apyrase to Fibrinolytic Therapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93933
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
HL095169
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APT THERAPEUTICS, INC.
4041 Forest Park Avenue SAINT LOUIS, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Adjunctive Use of Apyrase to Fibrinolytic Therapy
Agency: HHS
Contract: 1R43HL095169-01A1
Award Amount: $226,120.00
 

Abstract:

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I grant support, we will determine whether optimized human apyrases, in combination with tPA, induce rapid and sustain ed coronary artery recanalization without increasing bleeding risk. PUBLIC HEALTH RELEVANCE: We will utilize a coronary thrombotic model in dogs to validate whether human apyrase more effectively improve coronary patency than clopidogrel without increasing bleeding risk.

Principal Investigator:

Ridong Chen
3146086932
RCHEN@NIDUSCENTER.COM

Business Contact:

Ridong Chen
rchen@niduscenter.com
Small Business Information at Submission:

APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD SAINT LOUIS, MO 63141

EIN/Tax ID: 431947715
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No